Isotis Terug naar discussie overzicht

Peergroup ISOTIS op NASDAQ !

1. [verwijderd] 8 mei 2007 19:00

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   op 31 december 2006 was er een voorraad van 14 miljoen....op 31 december 2005 was dat 10 miljoen voorraad....omzet Q1 2006 was 9,8miljoen...
   omzet q1 2007 ?????
   
   
2. [verwijderd] 8 mei 2007 19:27

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   dat zou mooi zijn!
3. [verwijderd] 9 mei 2007 08:44

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   Er zullen wel wat eenmalige kosten zijn ivm met de overgang naar nasdaq. Niet alle kosten zijn genomen in het vorig jaar. Ik schat die kosten op ca usd 1,5 mln.
4. [verwijderd] 9 mei 2007 08:58

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   quote:

   MAX78 schreef:

   op 31 december 2006 was er een voorraad van 14 miljoen....op 31 december 2005 was dat 10 miljoen voorraad....omzet Q1 2006 was 9,8miljoen...
   omzet q1 2007 ?????
   
   

   tja ik laat me positief verrassen maar ik kom er niet bij dat je 40% meer voorraad gaat houden omdat je "natte vingerwerk" verwacht dat je meer gaat omzetten..er was m.i. al een duidelijk beeld vanwat de q1 periode zou gaan brengen...alleen natuurlijk het fda gebeuren in het q1 ...ik weet niet wat dat voorn impact heeft gehad op de verkopen. dat is even afwachten.
   
   
5. [verwijderd] 9 mei 2007 15:42

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   Cijfers OsteoTech.
   
   Watch out.
   
   Met vriendelijke groet.
   
   www.prnewswire.com/cgi-bin/stories.pl...
6. [verwijderd] 15 mei 2007 15:15

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   Cijfers IsoTis.
   
   Algemene indruk die men hier weergeeft is gematigd positief.
   
   U neemt het mij hopenlijk niet kwalijk dat ik daar iets anders over denk.
   
   Ikzelf ging uit van 5% tot 8%.
   
   www.prnewswire.com/cgi-bin/stories.pl...
   
   Vriendelijke groet.
7. [verwijderd] 15 mei 2007 15:27

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   wish de nadruk leggen op omzetgroei was er niet in dit eerste kwartaal bij.nadruk lag toch meer op:
   
   -fda gedoe
   
   -nasdaq overgang.
   
   -de voorbereiding aan de clinical trials (voordat de fda moeilijk ging doen)
   
   al met al dus een goed resultaat.
   
   een omzetgroei kan je weer gaan verwachten na fda uitspraak en introductie geheel nieuwe superieure isotis produkten.
   
   afwachten geblazen dus ....
8. [verwijderd] 15 mei 2007 15:30

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   quote:

   wishdom schreef:

   Cijfers IsoTis.
   
   Algemene indruk die men hier weergeeft is gematigd positief.
   
   U neemt het mij hopenlijk niet kwalijk dat ik daar iets anders over denk.
   
   Ikzelf ging uit van 5% tot 8%.
   
   www.prnewswire.com/cgi-bin/stories.pl...
   
   Vriendelijke groet.
   

   In dat geval ging het jou dus om 3 tot 6 ton meer omzet. Misschien komen die wel in het 2e kwartaal.
9. [verwijderd] 15 mei 2007 15:33

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   Meen me te herinneren dat je helemaal geen omzet verwachtte Wish? Ivm FDA gebeuren..
   Moet dit toch alles meevallen ;-)
10. [verwijderd] 15 mei 2007 15:36

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    TrendXL schreef:

    Meen me te herinneren dat je helemaal geen omzet verwachtte Wish? Ivm FDA gebeuren..
    Moet dit toch alles meevallen ;-)
    

    Das krek wak ook dach.
    Zal wel an mij liggen.
    
11. [verwijderd] 15 mei 2007 15:41

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Had aangegeven een omzet van 5 tot 8%.
    
    Max ging voor 10 tot 11 miljoen.
    
    Bot voor 11 miljoen.
    
    Maar ik mag als LTer toch wel teleurgesteld zijn.
    
    Hiervan gaat de koers niet omhoog.
    
    Emissie wordt voor een hoop minder $ars dan ik verwachtte,betekend toch een lagere bodem,ondanks dat ze die stukjes bij IBers kunnen plaatsen.
    
    Let wel,mijn LT plan staat als een huis,maar had,gezien de groeimarkt er toch wat meer van teruggezien.
    
    Vriendelijke groet.
12. [verwijderd] 15 mei 2007 15:43

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    wishdom schreef:

    Let wel,mijn LT plan staat als een huis,maar had,gezien de groeimarkt er toch wat meer van teruggezien.
    
    Vriendelijke groet.
    

    Dat hadden we denk ik allemaal wel.
    Tis niet anders.
    
    
13. [verwijderd] 15 mei 2007 15:49

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    het is dus 3 a 6 ton minder geworden dan je had verwacht. Let wel dit zijn kwartaalcijfers.
14. [verwijderd] 15 mei 2007 15:51

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Even terug koppelen wat ik wel en niet verwachtte.
    ------------------------------------------------------------------------------------------------------------------------------------------------------
    wishdom - 9 apr 07, 18:54 | Reageer | Quote | Zoek | Aanbevolen: 0
    
    Goedenavond,meneer Hadikmaar.
    
    Sorry dat ik zo kom binnenvallen,maar probeer je een kijkje te laten nemen binnen mijn gedachtegoed.
    
    Q3 2005 +37%
    Q4 2005 +34%
    
    Q3 2006 +25%
    Q4 2006 +15%
    
    U ziet dat er in Q4 2006 een behoorlijk verval is opgetreden.
    Hoe zou dat komen?(pending Accell)
    
    Kijkend naar Q1 2005 en 2006 met een + van 22% en 25% is het logisch als je die berekening toepast op Q1 2007 dat je rond de $11 miljoen uitkomt.
    
    Persoonlijk verwacht ik een + van niet meer dan 8% a 10%.
    
    
15. [verwijderd] 15 mei 2007 22:16

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Source: Alphatec Holdings, Inc.
    
    Alphatec Holdings, Inc. Drives Spinal Disorder Solution Technology and Announces the Launch of the New CONNECT II Cervical Structural Allograft Product
    CARLSBAD, Calif., May 15, 2007 (PRIME NEWSWIRE) -- Alphatec Holdings, Inc. (Nasdaq:ATEC), a leading medical device company focused on the design, development, manufacturing and marketing of products for the surgical treatment of spine disorders, announced today the release of the CONNECT(r) II Cervical Structural Allograft spacer. The CONNECT II product is integrated with Alphatec's proprietary cervical fusion instrumentation for maximum ease of use, procedural efficiency and further completes Alphatec's cervical fusion product line.
    
    
    "Allografts have a very strong following in the surgeon community due to their high success rates and ease of use and our CONNECT II product provides an excellent matrix for rapid perfusion leading to successful patient outcomes and we believe that it will become the allograft of choice for many surgeons," stated M. Ross Simmonds, Senior Vice President and Chief Operating Officer of Alphatec.
    
    Simmonds added, "The CONNECT II product complements our current DELTALOC(r) and DELTALOC(r) REVEAL anterior cervical plates, as well as our soon to be released anterior cervical plate that just received a 510(k) clearance from the FDA. This new product is one more example of our commitment to providing solutions targeted at serving the needs of the spinal disorder marketplace and enabling our surgeon customers to have additional technology options while utilizing Alphatec as their trusted spinal medical device partner."
    
    Technical Information
    
    CONNECT II Cervical Structural Allograft is produced from dense cancellous bone with a thick anterior cortical face to maximize compressive strength for optimal fusion. It is machined from the femoral head and other non-vertebral bone sources. The rapid perfusion and the CONNECT II cancellous matrix provides the structural and biological conditions necessary for optimal healing.
    
    The dimensions of CONNECT II are 14 millimeters in width, 14 millimeters in length, and the heights vary from 5 millimeters to 10 millimeters. All CONNECT II product sizes utilize a 7* lordotic angulation that re-establishes sagittal alignment and provides for maximum graft-to-host bone surface area. The range of sizes and versatile design provides optimal distraction and permits customization for a perfect fit for various patient specific needs, while the maximum graft-to-host bone surface contact area promotes excellent healing ability.
    
    CONNECT II is processed aseptically, freeze-dried, and shipped in a peel-pack. Some of the advantages of the freeze-dried packaging are that the product can be held at room temperature and eliminates the need for a freezer, dry ice or coolers. Although no thawing time is required, the product does require reconstitution in sterile saline. CONNECT II has a five year shelf life.
    
    Availability and Pricing
    
    The CONNECT II is now available for shipping and pricing is available on request.
    
    About Alphatec
    
    Alphatec (Nasdaq:ATEC) designs, develops, in-licenses, manufactures and markets innovative products for the surgical treatment of spine disorders. The company's broad product portfolio includes a variety of spinal implant products and systems focused on solutions addressing the cervical, thoracolumbar, intervertibral, minimally invasive, allograft, and motion preservation markets. The company's "surgeons' culture" emphasizes collaboration with spinal surgeons to conceptualize design and co-develop a broad range of products. State-of-the-art in-house manufacturing capabilities provide a unique competitive advantage, enabling the company to rapidly deliver customized solutions to meet surgeons' and patients' critical needs. Alphatec has 18 issued U.S. patents, one issued foreign patent and 24 pending patent applications, including sixteen pending U.S. applications, four pending international applications and four pending foreign national applications. Alphatec's principal product offerings are primarily focused on the U.S. spine fusion market, which is estimated to approach $5.9 billion in 2007. In addition to its U.S. operations, the company also markets a range of spine and orthopedic products in Japan through its subsidiary, Alphatec Pacific, Inc. For more information, please visit www.alphatecspine.com.
    
    Forward Looking Statements
    
    This press release may contain forward-looking statements that involve risks and uncertainty. Such statements are based on management's current expectations and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Alphatec cautions investors that there can be no assurance that actual results or business conditions will not differ materially from those projected or suggested in such forward-looking statements as a result of various factors, including, but not limited to, the following: Alphatec's ability to maintain its level of previously reported sales growth, Alphatec's ability to develop and expand its spine fusion business in the United States and Japan, the surgeon community's continued acceptance of allograft products, including CONNECT II, Alphatec's ability to expand and maintain a successful sales and marketing organization, continuation of favorable third party payor reimbursement for procedures performed using our products, unanticipated expenses or liabilities or other adverse events affecting cash flow or Alphatec's ability to achieve profitability, uncertainty of additional funding, uncertainty of success in developing any new products, failure to successfully introduce and develop new products, including products related to license agreements, failure to achieve acceptance of our products by the surgeon community, including CONNECT II, failure to obtain FDA clearance or approval for new products, Alphatec's ability to compete with other competing products and with emerging new technologies within and outside of spinal fusion, product liability exposure, patent infringement claims and claims related to our intellectual property. Please refer to the risks detailed from time to time in Alphatec's SEC reports, including quarterly reports on Form 10-Q, reports on Form 8-K and annual reports on Form 10-K. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, unless required by law.
    
16. [verwijderd] 16 mei 2007 20:06

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    
    
    Zimmer Holdings and Regeneration Technologies Enter Distribution Agreement for New Allograft Paste Implant
    
    
    WARSAW, Ind., and ALACHUA, Fla., May 16 /PRNewswire-FirstCall/ --
    Zimmer Holdings, Inc. (NYSE: ZMH; SMX: ZMH), a leader in the orthopaedic
    industry, and Regeneration Technologies, Inc. (RTI) (Nasdaq: RTIX), a
    leading processor of orthopaedic and other biologic implants, announced
    today that the companies have signed an exclusive 10-year distribution
    agreement for a new allograft bone paste.
    The next generation allograft bone paste will be delivered in flowable
    and moldable formulations, and is composed of inductive and carrier
    elements that are derived solely from human bone. The moldable formulation
    includes additional bone chips for osteoconduction.
    Handling and setting properties of the paste are designed so that the
    cohesive properties are maintained in a wet environment and so that the
    implant will conform and pack easily into the surgical site. The paste is
    provided pre-hydrated and at room temperature, and it is delivered sterile
    in a single stage delivery system.
    The paste is comprised of allograft tissue that must pass a rigorous in
    vivo rat assay designed to screen out potentially underperforming and
    inflammatory demineralized bone from use. Financial terms of the agreement,
    which is effective immediately, were not disclosed. Initial shipments of
    the paste to Zimmer are expected during the fourth quarter of 2007.
    "We are pleased to be able to work exclusively with RTI to combine the
    strength of their allograft bone paste with Zimmer's powerful distribution
    network," said David Dvorak, President and Chief Executive Officer of
    Zimmer Holdings, Inc. "Zimmer customers will now have direct access to an
    advanced demineralized bone paste product, which we believe is a natural
    complement to our joint reconstruction, spine, dental and trauma products
    and to our existing bone void fillers."
    "We are delighted to partner with Zimmer, a leader in orthopaedics, to
    bring this new paste implant to market," said Brian K. Hutchison, RTI's
    Chairman, President and Chief Executive Officer. "This next generation
    allograft bone paste offers surgeons ease of use and better performance for
    a variety of applications where a bone void filler is needed."
    About Zimmer
    Founded in 1927 and headquartered in Warsaw, Indiana, Zimmer is the
    worldwide #1 pure-play leader in designing, developing, manufacturing and
    marketing reconstructive and spinal implants, trauma and related
    orthopaedic surgical products. Zimmer has operations in more than 24
    countries around the world and sells products in more than 100 countries.
    Zimmer's 2006 sales were approximately $3.5 billion. The Company is
    supported by the efforts of nearly 7,000 employees worldwide.
    Visit Zimmer on the worldwide web at www.zimmer.com
    Zimmer Safe Harbor Statement
    This press release contains forward-looking statements within the safe
    harbor provisions of the Private Securities Litigation Reform Act of 1995
    based on current expectations, estimates, forecasts and projections about
    the orthopaedics industry, management's beliefs and assumptions made by
    management. Forward-looking statements may be identified by the use of
    forward-looking terms such as "may," "will," "expects," "believes,"
    "anticipates," "plans," "estimates," "projects," "assumes," "guides,"
    "targets," "forecasts," and "seeks" or the negative of such terms or other
    variations on such terms or comparable terminology. These statements are
    not guarantees of future performance and involve risks, uncertainties and
    assumptions that could cause actual outcomes and results to differ
    materially. These risks and uncertainties include, but are not limited to,
    our ability to successfully integrate acquired businesses, the outcome of
    the Department of Justice investigations announced in March 2005 and June
    2006, price and product competition, rapid technological development,
    demographic changes, dependence on new product development, the mix of our
    products and services, supply and prices of raw materials and products,
    customer demand for our products and services, control of costs and
    expenses, our ability to form and implement alliances, international
    growth, governmental laws and regulations affecting our U.S. and
    international businesses, including tax obligations and risks, product
    liability and intellectual property litigation losses, reimbursement levels
    from third-party payors, general industry and market conditions and growth
    rates and general domestic and international economic conditions including
    interest rate and currency exchange rate fluctuations. For a further list
    and description of such risks and uncertainties, see our periodic reports
    filed with the U.S. Securities and Exchange Commission. We disclaim any
    intention or obligation to update or revise any forward-looking statements,
    whether as a result of new information, future events or otherwise, except
    as may be set forth in our periodic reports. Readers of this document are
    cautioned not to place undue reliance on these forward- looking statements,
    since, while we believe the assumptions on which the forward-looking
    statements are based are reasonable, there can be no assurance that these
    forward-looking statements will prove to be accurate. This cautionary
    statement is applicable to all forward-looking statements contained in this
    document.
    About Regeneration Technologies, Inc.
    RTI processes allograft and xenograft tissue into shaped implants for
    use in orthopaedic and other surgeries with a commitment to science, safety
    and innovation.
    RTI also holds the patents on BioCleanse, the only proven tissue
    sterilization process validated to eliminate viruses, bacteria, fungi and
    spores from tissue without impacting the structural or biomechanical
    integrity of the tissue. The company has distributed more than half a
    million allograft implants sterilized with the BioCleanse process with zero
    incidence of infection. RTI is accredited by the American Association of
    Tissue Banks.
    Except for historical information, any statements made in this press
    release about the company's anticipated financial results, future
    operational results, regulatory approvals or changes to the company's
    agreements with its distributors are forward-looking statements subject to
    risks and uncertainties, such as those described in the company's public
    filings on file with the Securities and Exchange Commission. Actual results
    may differ materially from anticipated results reflected in these
    forward-looking statements. Copies of the company's SEC filings may be
    obtained by contacting the company or the SEC or by visiting RTI's web site
    at www.rtix.com or the SEC's web site at www.sec.gov.
    
    SOURCE Zimmer Holdings, Inc.
    
    --------------------------------------------------------------------------------
    
    
17. [verwijderd] 1 juni 2007 18:24

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Het had beter geweest als er IsoTis had gestaan,maar ik denk dat daar nog aan gewerkt wordt.
    
    Houd het scherp in de gaten.
    
    Deze dan maar als peer,in iedergeval eeen teken dat de zaak gevolgd wordt.
    
    Vriendelijke groet.
    
    New Coverage Sponsored by:
    Canaccord Adams Starts Orthovita (VITA) at Buy
    06-01-2007 11:29:12 AM
    More New Coverage
    
    
    
    Canaccord Adams initiates coverage on Orthovita (Nasdaq: VITA) with a Buy rating and $4.75 price target. Analyst William J. Plovanic said, "Orthovita is the market leader in the synthetic bone grafting market. By our estimates, Orthovita garnered 29% of the $161 million market, which is growing an estimated 22%, with DePuy a close second at 26%. We believe Orthovita has been successful for two reasons: 1) its focus on only biomaterials and 2) its build-out of a sales force dedicated solely to biologics
    
    Btw,ten tijden van de twee berichten op woensdag,had ik een vriend aan de telefoon,vlak voor beurs open,en ik zei dat het vandaag weleens neer de $10 kon.
    Toch teleurstellend verloop.
    
    Anyway,fijn weekend.
    
18. [verwijderd] 1 juni 2007 19:20

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    wish die tien staat er binnen enkele weken...nog even geduld hebben.
19. [verwijderd] 1 juni 2007 19:57

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    wishdom schreef:

    Het had beter geweest als er IsoTis had gestaan,maar ik denk dat daar nog aan gewerkt wordt.
    
    Houd het scherp in de gaten.
    
    Deze dan maar als peer,in iedergeval eeen teken dat de zaak gevolgd wordt.
    
    Vriendelijke groet.
    
    New Coverage Sponsored by:
    Canaccord Adams Starts Orthovita (VITA) at Buy
    06-01-2007 11:29:12 AM
    More New Coverage
    
    
    
    Canaccord Adams initiates coverage on Orthovita (Nasdaq: VITA) with a Buy rating and $4.75 price target. Analyst William J. Plovanic said, "Orthovita is the market leader in the synthetic bone grafting market. By our estimates, Orthovita garnered 29% of the $161 million market, which is growing an estimated 22%, with DePuy a close second at 26%. We believe Orthovita has been successful for two reasons: 1) its focus on only biomaterials and 2) its build-out of a sales force dedicated solely to biologics
    
    Btw,ten tijden van de twee berichten op woensdag,had ik een vriend aan de telefoon,vlak voor beurs open,en ik zei dat het vandaag weleens neer de $10 kon.
    Toch teleurstellend verloop.
    
    Anyway,fijn weekend.
    
    

    Wie is Canaccord Adams (heb ik nog nooit van gehoord). Merril Lynch Capital en Sillicon Vally Bank dat zijn pas namen. Wanneer die met een koopadvies komen dan ...
    
    Prettig weekend
20. [verwijderd] 1 juni 2007 20:04

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    About Canaccord Adams
    
    
    Canaccord Adams is committed to fueling the entrepreneurial economy by identifying emerging opportunities and facilitating long-term growth. We bring businesses and investors together, powering the diverse engines that drive global innovation and success.
    
    Our capital markets professionals are dedicated to client service, combining the passion of an independent culture with the professionalism of experienced management. We generate actionable, idea-driven research. We structure and distribute high-impact transactions. We provide effective liquidity and high-quality execution in Canada, the United States and Europe. Operating in eight offices internationally, our integrated team brings unique global perspective and focused industry expertise to our full service offerings in Metals and Mining, Energy, Technology, Life Sciences, Real Estate and Gaming, Consumer and Industrial Growth.
    
    To learn more about how Canaccord Adams can move you forward, please visit:
    
    Research
    Sales and Trading
    Investment Banking
    Corporate Services
    Canaccord Adams is a leading independent financial services firm committed to fostering the entrepreneurial economy by bringing corporate and institutional clients unique perspective on global investment opportunities. With operations in research, sales and trading, and investment banking, our 225 professionals seek out emerging opportunities in our key sectors - Mining and Metals, Energy, Technology, Life Sciences, Real Estate and Gaming, Consumer and Industrial Growth. Located in nine offices internationally, our experienced team generates focused, actionable ideas that identify opportunity and facilitate growth.